$48.61
Live
0.84%
Downside
Day's Volatility :1.47%
Upside
0.63%
22.75%
Downside
52 Weeks Volatility :58.78%
Upside
46.64%
Period | Crispr Therapeutics Ag | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -13.02% | 3.6% | 0.0% |
6 Months | -12.11% | 10.2% | 0.0% |
1 Year | 22.0% | 19.6% | 0.0% |
3 Years | -49.6% | 16.8% | -23.0% |
Market Capitalization | 4.1B |
Book Value | $23.29 |
Earnings Per Share (EPS) | -3.2 |
PEG Ratio | -0.21 |
Wall Street Target Price | 80.92 |
Profit Margin | -131.44% |
Operating Margin TTM | -29257.25% |
Return On Assets TTM | -9.77% |
Return On Equity TTM | -14.0% |
Revenue TTM | 202.2M |
Revenue Per Share TTM | 2.48 |
Quarterly Revenue Growth YOY | -99.3% |
Gross Profit TTM | -570.7M |
EBITDA | -335.2M |
Diluted Eps TTM | -3.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.67 |
EPS Estimate Next Year | -4.99 |
EPS Estimate Current Quarter | -1.52 |
EPS Estimate Next Quarter | -1.4 |
What analysts predicted
Upside of 66.47%
Sell
Neutral
Buy
Crispr Therapeutics Ag is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Crispr Therapeutics Ag | 4.66% | -12.11% | 22.0% | -49.6% | 22.15% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Crispr Therapeutics Ag | 13.4 | NA | -0.21 | -5.67 | -0.14 | -0.1 | NA | 23.29 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Crispr Therapeutics Ag | Buy | $4.1B | 22.15% | 13.4 | -131.44% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Crispr Therapeutics Ag
Revenue is up for the last 2 quarters, 504.0K → 517.0K (in $), with an average increase of 2.5% per quarter
Netprofit is down for the last 3 quarters, 89.34M → -126.40M (in $), with an average decrease of 119.5% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 56.2%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 94.4%
Capital Research & Mgmt Co - Division 3
ARK Investment Management LLC
Sumitomo Mitsui Trust Group Inc
Nikko Asset Management Americas Inc
BlackRock Inc
T. Rowe Price Investment Management,Inc.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Organization | Crispr Therapeutics Ag |
Employees | 407 |
CEO | Dr. Samarth Kulkarni Ph.D. |
Industry | Health Technology |
International Select Dividend Ishares
$48.61
-0.63%
Vanguard Ultra Short Bond Et
$48.61
-0.63%
Core Scientific Inc
$48.61
-0.63%
Integer Holdings Corp
$48.61
-0.63%
Liberty Global Plc - Class C Shares
$48.61
-0.63%
Pampa Energia Sa
$48.61
-0.63%
Icf International Inc
$48.61
-0.63%
Pacific Premier Bancorp Inc
$48.61
-0.63%
Macy's, Inc.
$48.61
-0.63%